30 facts you need to know: Your Covid cribsheet

We get a lot of e-mails and private messages along these lines “do you have a source for X?” or “can you point me to mask studies?” or “I know I saw a graph for mortality, but I can’t find it anymore”. And we understand, it’s been a long 18 months, and there are so many statistics and numbers to try and keep straight in your head.

So, to deal with all these requests, we decided to make a bullet-pointed and sourced list for all the key points. A one-stop-shop.

Here are key facts and sources about the alleged “pandemic”, that will help you get a grasp on what has happened to the world since January 2020, and help you enlighten any of your friends who might be still trapped in the New Normal:

“Covid deaths” – Lockdowns – PCR Tests – “asymptomatic infection” – Ventilators – Masks – Vaccines – Deception & Foreknowledge

PART I: “COVID DEATHS” & MORTALITY

1. The survival rate of “Covid” is over 99%.

2. There has been NO unusual excess mortality.

3. “Covid death” counts are artificially inflated.

4. The vast majority of covid deaths have serious comorbidities.

5. Average age of “Covid death” is greater than the average life expectancy.

6. Covid mortality exactly mirrors the natural mortality curve.

7. There has been a massive increase in the use of “unlawful” DNRs.

PART II: LOCKDOWNS

8. Lockdowns do not prevent the spread of disease.

9. Lockdowns kill people.

10. Hospitals were never unusually over-burdened.

PART III: PCR TESTS

11. PCR tests were not designed to diagnose illness.

12. PCR Tests have a history of being inaccurate and unreliable.

13. The CT values of the PCR tests are too high.

14. The World Health Organization (Twice) Admitted PCR tests produced false positives.

15. The scientific basis for Covid tests is questionable.

PART IV: “ASYMPTOMATIC INFECTION”

16. The majority of Covid infections are “asymptomatic”.

17. There is very little evidence supporting the alleged danger of “asymptomatic transmission”. 

PART V: VENTILATORS

18. Ventilation is NOT a treatment for respiratory viruses.

19. Ventilators killed people.

PART VI: MASKS

20. Masks don’t work.

21. Masks are bad for your health.

22. Masks are bad for the planet.

PART VII: VACCINES

23. Covid “vaccines” are totally unprecedented.

24. Vaccines do not confer immunity or prevent transmission.

25. The vaccines were rushed and have unknown longterm effects.

26. Vaccine manufacturers have been granted legal indemnity should they cause harm.

PART VIII: DECEPTION & FOREKNOWLEDGE

27. The EU was preparing “vaccine passports” at least a YEAR before the pandemic began.

28. A “training exercise” predicted the pandemic just weeks before it started.

29. Since the beginning of 2020, the Flu has “disappeared”.

30. The elite have made fortunes during the pandemic. 

Read here (OffGuardian, Sept 22, 2021)

Viral questions

A look at some of the most commonly asked questions around the coronavirus pandemic.

• How would COVID-19 vaccine makers adapt to variants?
• How do we know the COVID-19 vaccines are safe?
• How are experts tracking variants of the coronavirus?
• Which COVID-19 tests are required for international travel?

And more...

Read here (AP, Feb 25, 2021)

Experts answer the biggest Covid vaccine questions

‘The lack of informed messaging from the Trump administration, combined with the range of different COVID vaccines, the emergence of new coronavirus variants, and inconsistent state and municipal rollout plans, have caused confusion and driven vaccine hesitancy. Scientific American asked Namandjé Bumpus, a pharmacologist at Johns Hopkins Medicine in Baltimore, and Ashley Lauren St. John, an immunologist at Duke-NUS Medical School in Singapore to answer some of the biggest questions about the currently available COVID vaccines:

• Should you get an authorized COVID vaccine now if you are eligible?
• Should you get vaccinated if you have already had COVID?
• How should you interpret vaccine efficacy—what does “95 percent efficacy” or “66 percent efficacy” even mean?
• If you get the vaccine and still get infected, does the vaccine still make a difference? 
• Will it prevent severe disease or death?
• Do the vaccines protect against the new virus variants, including those first identified in the U.K., South Africa and Brazil?
• What is the difference between mRNA and viral vector vaccines?
• Is there a “best” vaccine?
• Will the vaccine protect you from giving the virus to others?
• Will the vaccine’s effectiveness “wear off” over time?
• Should you be worried about allergic reactions to the vaccine?
• How can you ensure you’re getting a legitimate, authorized vaccine?

Read here (Scientific American, Feb 19, 2021)

‘Pure, liquid hope’: What the vaccine means to me as a GP

‘Clinicians everywhere are all nervous about what will happen if that loosening of restrictions occurs too quickly. Though death from Covid among the under-50s is relatively rare, it can still be a terrible, terrifying disease, capable of rendering its victims breathless and exhausted for weeks (and in some cases, months) after its fevers have run their course. One of my own patients, a nurse in his 20s, used to run 10km three or four times a week. The staff vaccination programme was too late for him: he caught Covid on the wards just before Christmas. Though he’s now back at work, he still hasn’t recovered sufficiently to be able to get back to running.

‘For the next six months, all my colleagues and I will be vaccinating as needed, as many hours as we’re able to. This week I’ve been gladly trudging the streets in the snow, vaccinating our housebound patients, and there aren’t too many still to go. In Scotland, the programme is anticipated to go on at least until 31 July, and the hope is that everyone over 50 will have had a first dose by May.

‘The numbers are daunting, but there’s a spirit of anticipation and celebration in the air. Many are starting to dare to plan for a world post-Covid, and I’m tempted to share that optimism. Opening my first box of vials, I thought of a friend in Orkney, a GP who’d already vaccinated all the over-80s of his practice, and who’d begun to call in the over-70s. We met briefly in Kirkwall, outdoors, on my journey from Orkney back to Edinburgh. “How did it feel to get started?” I asked him.

“I almost wept as I opened that box of vials,” he said, smiling at the memory. “Each one was hope – pure, liquid hope.”

Read here (The Guardian, Feb 11, 2021)

Four principles for urgent pharma action to combat Covid-19

‘Collaboration is needed between pharmaceutical companies and governments to combat the spread of COVID-19 and accelerate access to tests, treatments and vaccines. Norway, which co-chairs the Facilitation Council of the ACT-Accelerator, is committed to ensuring the global vaccination effort is managed effectively. Here are four principles which could ensure equitable access to COVID-19 tools and health products, particularly for low and middle-income countries:

• Principle 1: File for registration rapidly, widely and on the basis of the most rigorous standards
• Principle 2: Price health technologies fairly
• Principle 3: Expand production and supply capacity
• Principle 4: Transparency

Read here (World Economic Forum, Feb 9, 2021)

Wealth increase of 10 men during pandemic could buy vaccines for all: Oxfam

‘The combined wealth of the world's 10 richest men rose by $540bn (£400bn) during the pandemic, according to Oxfam. The charity claims this amount would be enough to prevent the world from falling into poverty because of the virus, and pay for vaccines for all. The organisation is urging governments to consider taxes on the super-rich. Oxfam's report comes as global leaders gather virtually for the World Economic Forum's "Davos Dialogue" meeting.’

Read here (BBC, Jan 26, 2021)

When will the pandemic end? (McKinsey & Co update, Jan 20, 2021)

‘This article updates our earlier perspectives on when the coronavirus pandemic will end. Transition toward normalcy in the United States remains most likely in the second quarter of 2021 and herd immunity in the third and fourth quarters, but the emergence of new strains and a slow start to vaccine rollout raise real risks to both timelines. We also add a perspective for the United Kingdom...

Transition toward normalcy

‘A transition toward normalcy will occur when COVID-19 mortality falls and the disease is de-exceptionalized in society. COVID-19 will not disappear during this transition, but will become a more normal part of the baseline disease burden in society (like flu, for example), rather than a special threat requiring exceptional societal response. During this transition, controlling the spread of SARS-CoV-2 will still require public-health measures (such as continued COVID-19 testing and mask use in many settings), but mortality will fall significantly, allowing greater normalization of business and social activities. This will be driven by a combination of early vaccine rollout (which, being directed first at those at greatest risk, should reduce deaths faster than cases), seasonality, increasing natural immunity, and stronger public-health response.’

Read here (McKinsey & Co update, Jan 20, 2021)

Covid-19 herd immunity unlikely in 2021 despite vaccines: UN

‘The World Health Organization’s chief scientist warned that even as numerous countries start rolling out vaccination programs to stop COVID-19, herd immunity is highly unlikely this year.

‘At a media briefing on Monday (Jan 11), Dr Soumya Swaminathan said it was critical countries and their populations maintain strict social distancing and other outbreak control measures for the foreseeable future. In recent weeks, Britain, the US, France, Canada, Germany, Israel, the Netherlands and others have begun vaccinating millions of their citizens against the coronavirus.’

Read here (Channel News Asia, Jan 12, 2021)

There are four types of Covid-19 vaccines: Here’s how they work

‘The fight against COVID-19 has seen vaccine development move at record speed, with more than 170 different vaccines in trials. But how are they different from each other and how will they protect us against the disease?

‘There are more vaccine candidates simultaneously in the pipeline for COVID-19 than ever before for an infectious disease. All of them are trying to achieve the same thing – immunity to the virus, and some might also be able to stop transmission. They do so by stimulating an immune response to an antigen, a molecule found on the virus. In the case of COVID-19, the antigen is typically the characteristic spike protein found on the surface of the virus, which it normally uses to help it invade human cells.

‘The four main types of Covid-19 vaccines: There are four categories of vaccines in clinical trials: (1) Whole virus, (2) Protein subunit, (3) Viral vector and (4) Nucleic acid (RNA and DNA). Some of them try to smuggle the antigen into the body, others use the body’s own cells to make the viral antigen.’

Read here (Gavi, as Jan 2021)

Watch here (Gavi, Youtube, as Jan 2021)

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine (Pfizer clinical trial)

BACKGROUND: ‘Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently.’

METHODS: ‘In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety.’

RESULTS: ‘A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups.’

CONCLUSIONS: ‘A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728. opens in new tab.)’

Read here (New England Journal of Medicine, Dec 31. 2020)

The science behind an RNA vaccine

‘In just 10 months, a vaccine developed by Pfizer and BioNTech has been approved by Britain for emergency use to prevent Covid-19. Another by Moderna is being evaluated for emergency use authorisation by several regulators, including the United States Food and Drug Administration...

‘This 10-month timeline for vaccines to get from concept to licensing is ground-breaking; most take more than 10 years to reach this stage. There are several other RNA vaccines in the pipeline, including the one our team at Duke-NUS Medical School is working on in partnership with Arcturus Therapeutics. Here is the science behind such vaccines...’

Read here (Straits Times, Dec 7, 2020)

Neutralising the threat of Covid-19

Informative and interesting talk with Q&A relevant to Malaysia, live-streamed on Dec 7, 2020. Professor William James, is Professor of Virology and Tutor in Medical Sciences, Jeffrey Cheah Professorial Fellow, and is attached to The Sir William Dunn School of Pathology. He is currently contributing to the work on the Oxford University AstraZeneca COVID-19 vaccine. The talk is moderated by Prof. Abhi Veerakumarasivam, Co-Chair & Professor, ASEAN Young Scientists Network & Sunway University.

View here (YouTube, Dec 7, 2020)

Designing vaccines for people, not profits

‘The Covid-19 crisis is a perfect test of whether a more public-health-oriented approach to innovation and production will prevail in the years ahead. While Pfizer is sticking with the model of maximising shareholder value, AstraZeneca has at least pledged not to profit from its vaccine ‘during the pandemic.’ Yet, despite all the public investment that underwrote these innovations, the process will remain opaque, leaving one to wonder if AstraZeneca is actually ready to prioritise public health over profit and offer its vaccine at cost.

‘While the recent vaccine news has brought hope, it also has exposed the pharmaceutical industry’s broken business model, casting doubt on the prospects of delivering a people’s vaccine and achieving health for all. Business as usual may allow us to scrape by in this crisis. But there is a better way to do things. Before the next pandemic arrives, we must recognise vaccines as global health commons, and start to reorient the innovation system toward symbiotic public-private partnerships governed in the public interest.’

Read here (Social Europe, Dec 2, 2020)

Covid vaccines: Calling the shots

‘The lesson of the coronavirus vaccine response is that a few billion dollars a year spent on additional basic research could prevent a thousand times as much loss in death, illness, and economic destruction. At a news conference, US health adviser, Anthony Fauci, highlighted the spike protein work. “We shouldn’t underestimate the value of basic biology research,” Fauci said. Exactly. But as many authors, such as Mariana Mazzacuto have shown, state funding and research has been vital to development of such products.

‘What better lesson can we learn from the COVID vaccine experience than that the multi-national pharma companies should be publicly owned so that research and development can be directed to meet the health and medical needs of people rather than to the profits of these companies. Then the necessary vaccines can get to the billions in the poorest countries and circumstances rather than to just those countries and people who can afford to pay the prices set by these companies.

“This is the people’s vaccine,” said corporate critic Peter Maybarduk, director of Public Citizen’s Access to Medicines program. “Federal scientists helped invent it and taxpayers are funding its development. … It should belong to humanity.”

Read here (The Bullet, Dec 2, 2020)

What you need to know about the Pfizer, Moderna and AstraZeneca vaccines

‘All three drugmakers have moved at record speed, and the first shots of the Pfizer and Moderna vaccines could be given in the coming weeks. This article answers a list of questions that ordinary people need to know before they commit to the vaccinations.’

Read here (Washington Post, Nov 30, 2020)

AstraZeneca says its Covid-19 vaccine needs 'additional study'

‘The head of British drug manufacturer AstraZeneca said on Thursday (Nov 26) further research was needed on its COVID-19 vaccine after questions emerged over the protection it offers, but the additional testing is unlikely to affect regulatory approval in Europe.

‘Instead of adding the trial to an ongoing US process, AstraZeneca might launch a fresh study to evaluate a lower dosage of its vaccine that performed better than a full dosage, AstraZeneca chief executive Pascal Soriot was quoted as saying in a Bloomberg News report.’

Read here (Channel News Asia, Nov 27, 2020)

Scientists are puzzling over one crucial number as they evaluate the Oxford-AstraZeneca coronavirus vaccine

‘The Oxford-AstraZeneca vaccine candidate is given to people as two doses, at least one month apart. The trial data, which comes from late-stage studies in the UK, Brazil and South Africa, suggests that the vaccine is 62% effective if people get two full doses, but 90% effective when they get a half-strength version of the first dose. The information was provided in a press release and hasn't been published in a peer-reviewed journal. AstraZeneca and Oxford said they're submitting the results for review and publication.’

Read here (Business Insider, Nov 24, 2020)

Moderna's chief medical officer says that vaccine trial results only show that they prevent people from getting sick — not necessarily that recipients won't still be able to transmit the virus

‘Moderna Chief Medical Officer Tal Zaks told Axios that the public should not "over-interpret" the vaccine trial results to assume life could go back to normal after adults are vaccinated. "They do not show that they prevent you from potentially carrying this virus transiently and infecting others," Zaks told Axios.  While he believes, based on the science, that it's likely that vaccine does prevent transmission, but said there's still no solid proof of that yet. "I think it's important that we don't change behavior solely on the basis of vaccination," he said.’

Read here (Business Insider, Nov 24, 2020)

The efficacy of the Sputnik V vaccine is 91.4%, based on the second interim analysis

‘The Sputnik V vaccine is based on a well-studied human adenoviral vector platform that has proven safe and effective with no long-term side effects in more than 250 clinical trials globally conducted during the past two decades - while the history of the use of human adenoviruses in vaccine development began in 1953. More than 100,000 people have received approved and registered drugs based on human adenoviral vectors. The uniqueness of the Russian vaccine lies in the use of two different human adenoviral vectors which allows for a stronger and longer-term immune response as compared to the vaccines using one and the same vector for two doses.’

Read here (Sputnik V, Nov 23, 2020)

Oxford vaccine: How did they make it so quickly?

‘Ten years' vaccine work achieved in about 10 months. Yet no corners cut in designing, testing and manufacturing... They are two statements that sound like a contradiction, and have led some to ask how we can be sure the Oxford vaccine - which has published its first results showing it is highly effective at stopping Covid-19 - is safe when it has been made so fast. So, this is the real story of how the Oxford vaccine happened so quickly.’

Read here (BBC, Nov 23, 2020)